A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

PURPOSE: Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian population. METHODS: Camrelizumab was administere...

Descripción completa

Detalles Bibliográficos
Autores principales: Lickliter, Jason D, Gan, Hui K, Voskoboynik, Mark, Arulananda, Surein, Gao, Bo, Nagrial, Adnan, Grimison, Peter, Harrison, Michelle, Zou, Jianjun, Zhang, Lianshan, Luo, Stacey, Lahn, Michael, Kallender, Howard, Mannucci, Andrea, Somma, Catello, Woods, Katherine, Behren, Andreas, Fernandez-Penas, Pablo, Millward, Michael, Meniawy, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090185/
https://www.ncbi.nlm.nih.gov/pubmed/32256049
http://dx.doi.org/10.2147/DDDT.S243787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090185/
https://www.ncbi.nlm.nih.gov/pubmed/32256049
http://dx.doi.org/10.2147/DDDT.S243787

Ejemplares similares